Genmab — Oktober 2016
-
Når man har oplevet en finanskrise og set hvordan markedet i en periode var fuldstændig ligeglad med potentiale og fundamentale i de enkelte aktier, så ved man, at intet er umuligt ved en dyb generel korrektion. Det er vist det McJean lufter her i tråden.
-
Genmab (Buy)
We close in on a busy couple of months with the CMD in November and the ASH conference in December, which we believe could drive the share price higher. Our key focus is on longer-term data from the CASTOR and POLLUX studies and the dive deeper into the mechanism of actions of daratumumab, which could possibly become key ASH presentations. -
AB snuppede lige 21.000 netto i lukkeaktionen
god aften -
Genmab (OMX: GEN) will hold an ASH 2016 Data Review Meeting on Monday 5 December 2016 at 8:00 PM Pacific Time (5:00 AM CET / 4:00 AM GMT on 6 December). The event will take place at the Manchester Grand Hyatt in San Diego, California and will include presentations by external key opinion leaders.
-
Mcjean- jeg mener vi på ASH kan forvente nye PFS data. Jeg forventer halen på Kaplan-Maier kurven er forlænget. Det er vigtigt for analytikernes topsalgsestimater.
-
Ja Mcjean har ret i at medianen ikke nås til ASH. Det må vi da håbe
-
-
NBI er i BULL market
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind